A Comprehensive Approach for Progress
Ending the Epidemic
HIV-Specific Neutralizing Antibodies by Target
A number of broadly neutralizing antibodies that target various regions of HIV’s Env protein are being developed for HIV prevention.
Cumulative Number of PrEP Initiations for Q1 of 2023
Pregnant and Lactating People (PLP) in Ongoing HIV Prevention Trials
Lessons Learned for Delivery PrEP Implementation
Current trends for investment in HIV prevention R&D by technology
COMPASS Africa Campaigns: Building CSO power and impact Infographic
Status Updates on Ongoing and Planned HIV Prevention Trials
The world is grappling with the far-reaching impacts of the COVID-19 pandemic and the HIV prevention field is no different. Most trials investigating new biomedical HIV prevention products have paused, citing concerns for the safety of trial participants and the study teams.
How COVID-19 is impacting research varies by trial and site, and efforts are ongoing to minimize impact on trial timelines and data. AVAC will continue to monitor developments—watch this space.
Ongoing Studies for the Treatment and Prevention of the COVID-19 Virus
This table is a work in progress, as this is an incredibly dynamic landscape. Over the past month, the scientific community has accelerated development of COVID-19 diagnostics, therapeutics and a potential vaccine. This document also links to a number of resources available to track these developments.
In addition, a collaborative project of the COVID-19 Working Group NY, the PrEP4All Collaboration and Treatment Action Group offers concise overviews and analyses of key research areas.
AIDS Vaccines by the Numbers: Trials, discoveries, money and more
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward. The graphics below represent key facts about the AIDS vaccine field.